Dr. Douglas Brenneman received his PhD in pharmacology and toxicology from the University of Kansas and continued his postdoctoral training in central nervous system pharmacology and developmental neurobiology in the laboratory of Dr. Phillip G. Nelson, a pioneer in the use of primary neural culture systems. While at the NIH, he studied the the ability of neuropeptides to support nerve cell growth and survival. As a result of this work, he is the co-inventor of davunetide, a peptide that proceeded to clinical trials for the treatment of progressive supranuclear palsy. Dr. Brenneman’s current work with Kannalife Science focuses on neuroprotection and neuroinflammation. He identified KLS-13019 as a lead compound for the treatment of peripheral neuropathy. The molecular targets of KLS-13019 have also been found to be relevant to the treatment of Parkinson’s disease, forming the basis of his work supported by the MJFF.